BIIB: Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

New alert via PocketInfo for BIIB:

Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

Press Releases: http://www.biogenidec.com/press_releases.aspx?ID=5980
SEC Filings: http://www.biogenidec.com/sec_filings.aspx?ID=5916
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8